Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Conduct Clinical Development Based on Assumption That There Are Ethnic Differences
January 5, 2009
- Most Women Have Not Been Examined for Breast Cancer Despite Willingness
December 22, 2008
- High % of ED Patients with Underlying Conditions Satisfied with Levitra: Bayer Schering
December 22, 2008
- Nichi-Iko Merges 3 Subsidiaries
December 22, 2008
- GLP-1 Analogues, DPP-4 Inhibitors to Cut Treatment Cost for Diabetes: Dr Kobayashi
December 22, 2008
- Daiichi Sankyo Applies for Olmesartan + Ca Blocker Combination
December 22, 2008
- Relenza Should Be More Effectively Used in Combination with Tamiflu: Prof. Matsumoto
December 22, 2008
- DB of Medical Bills to Help Drug Risk Assessment
December 22, 2008
- Prescription of Tamiflu by Phone to Be Permitted upon Onset of Pandemic of New-Type Flu
December 22, 2008
- Aspirin Should Be Reimbursed at Low Doses to Prevent Arteriosclerotic Diseases
December 22, 2008
- Janssen Offers Opportunities to Experience Virtual AD/HD
December 22, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 22, 2008
- REGULATORY NEWS IN BRIEF
December 22, 2008
- Non-Recommendation of HPV Screening Meets Strong Objections
December 22, 2008
- Astellas to Identify Its 3rd and 4th Franchise Fields
December 22, 2008
- Daiichi Sankyo Starts PIII Trial of DU-176b
December 22, 2008
- Urination Management Services Should Be Reimbursed: Dr Kuroda
December 22, 2008
- GSK Enhances Its Presence in CNS Field with Lamictal
December 22, 2008
- Takeda, CanBas Start PII Trial for CBP501 for Malignant Pleural Mesothelioma in US
December 22, 2008
- Galderma Aims at No. 1 Position in Dermatology
December 22, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…